Merck & Co Inc
NYSE:MRK
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
96.31
132.96
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Merck & Co Inc
Merck & Co Inc
Stock-Based Compensation
Merck & Co Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Merck & Co Inc
NYSE:MRK
|
Stock-Based Compensation
$741m
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
10%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Stock-Based Compensation
$698m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
|
Zoetis Inc
NYSE:ZTS
|
Stock-Based Compensation
$72m
|
CAGR 3-Years
8%
|
CAGR 5-Years
1%
|
CAGR 10-Years
10%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
Glance View
Merck & Co., Inc., a global leader in the pharmaceutical industry, has been on a transformative journey that reflects its commitment to innovation and improving health outcomes around the world. Founded in 1891, the company has grown into a powerhouse known for its diverse product portfolio, which includes groundbreaking vaccines, oncology therapies, and treatments for chronic diseases. With a rich history of fostering research and development, Merck invests heavily in scientific advancements, positioning itself at the forefront of medical breakthroughs. This dedication has led to the successful launch of key products, such as the human papillomavirus (HPV) vaccine Gardasil and the cancer immunotherapy Keytruda, which has gained significant traction and revenue, making it one of the top-selling drugs globally. As an investor, understanding Merck's strategic direction is crucial. The company is not only focused on maintaining its legacy in pharmaceuticals but also on expanding its presence in biopharma through collaborations and acquisitions, enhancing its pipeline of potential therapies. With a robust dividend history, Merck has demonstrated its commitment to returning value to shareholders, signifying financial stability and confidence in ongoing business fundamentals. Furthermore, as the global demand for innovative health solutions accelerates, Merck's proactive approach to addressing emerging health challenges positions it for sustainable growth. For investors, the combination of Merck’s rich heritage, innovative spirit, and sound financial practices creates an appealing narrative that carries potential for long-term returns.
See Also
What is Merck & Co Inc's Stock-Based Compensation?
Stock-Based Compensation
741m
USD
Based on the financial report for Sep 30, 2024, Merck & Co Inc's Stock-Based Compensation amounts to 741m USD.
What is Merck & Co Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
10%
Over the last year, the Stock-Based Compensation growth was 19%. The average annual Stock-Based Compensation growth rates for Merck & Co Inc have been 16% over the past three years , 14% over the past five years , and 10% over the past ten years .
You don't have any saved screeners yet
